Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 10/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29437164 | 0.92 | ALDH1A1 (0.70) | NAMPTALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL21246641 | 0.92 | ALDH1A1 (0.70) | NAMPTALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL21246591 | 0.91 | NAMPT (0.61) | NAMPTALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL29437173 | 0.90 | NAMPT (0.62) | NAMPTALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL29437174 | 0.90 | NAMPT (0.62) | NAMPTALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL21227033 | 0.90 | NAMPT (0.62) | NAMPTALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL21222740 | 0.90 | NAMPT (0.62) | NAMPTALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL29437163 | 0.90 | NAMPT (0.62) | NAMPTALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL21227038 | 0.90 | NAMPT (0.62) | NAMPTALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL21246579 | 0.89 | NAMPT (0.72) | NAMPTALDH1A1LMNAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391647-B2 | Benzamide compound and preparation method, use, and pharmaceutical composition thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2025-08-19 | — | — | US | disclosed |
| US-20230099912-A1 | BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2023-03-30 | — | — | US | disclosed |
| EP-3747866-B1 | BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF | INST MATERIA MEDICA CAMS (CN) | 2023-03-01 | — | — | EP | disclosed |
| US-11518744-B2 | Benzamide compound and preparation method, use, and pharmaceutical composition thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-12-06 | — | — | US | disclosed |
| US-11518744-B2 | Benzamide compound and preparation method, use, and pharmaceutical composition thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-12-06 | — | — | US | disclosed |
| CN-110092743-B | Benzamide compound, preparation method, application and pharmaceutical composition thereof | 中国医学科学院药物研究所 | 2022-03-15 | — | — | CN | disclosed |
| US-20210047270-A1 | BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2021-02-18 | — | — | US | disclosed |
| US-20210047270-A1 | BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2021-02-18 | — | — | US | disclosed |
| EP-3747866-A1 | BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019149223-A1 | BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF | 中国医学科学院药物研究所 | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391647-B2 | Benzamide compound and preparation method, use, and pharmaceutical composition thereof | JAK2, STAT3, STAT5A | NAMPT 478/4885ALDH1A1 635/4885LMNA 2434/4885 |
| US-20230099912-A1 | BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF | JAK2, STAT3, STAT5A | NAMPT 478/4885ALDH1A1 635/4885LMNA 2434/4885 |
| US-20210047270-A1 | BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF | JAK2, STAT3, STAT5A | NAMPT 478/4885ALDH1A1 635/4885LMNA 2434/4885 |
| US-11518744-B2 | Benzamide compound and preparation method, use, and pharmaceutical composition thereof | JAK2, STAT3, STAT5A | NAMPT 478/4885ALDH1A1 635/4885LMNA 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.